Last updated on October 6th, 2020 at 01:29 pm
In a not very surprising development, Occupational Safety and Health Administration (OSHA) has announced a delay in the implantation of their Final Rule titled “Improve Tracking of Workplace Injuries and Illnesses”.
There was a sizable hue and cry about this proposed regulation with considerable discussion among drug test service providers and of course the employers.
The Manufacturers Center for Legal Action (MCLA) in conjunction with other organizations filed a motion to challenge the implementation of this rule. The Department of Labor (DOL) and OSHA have announced a delay for the implementation of this final rule until November 1, 2016.
Several questions had been directed to OSHA to which there was not a formal response except as given below.
In the final rule, you state that drug tests cannot be performed unless the test can show impairment. I quote from the rule as follows:
Page 29673: “Although drug testing of employees may be a reasonable workplace policy in some situations, it is often perceived as an invasion of privacy, so if an injury or illness is very unlikely to have been caused by employee drug use, or if the method of drug testing does not identify impairment but only use at some time in the recent past, requiring the employee to be drug tested may inappropriately deter reporting.”
Page 29673: “To strike the appropriate balance here, drug testing policies should limit post-incident testing to situations in which employee drug use is likely to have contributed to the incident, and for which the drug test can accurately identify impairment caused by drug use.”
On the FAQs, the following is stated: “The rule does not prohibit drug testing of employees. It only prohibits employers from using drug testing, or the threat of drug testing, as a form of retaliation against employees who report injuries or illnesses. If an employer conducts drug testing to comply with the requirements of a state or federal law or regulation, the employer’s motive would not be retaliatory and this rule would not prohibit such testing.”
With above references my questions are as follows:
1. Can you identify a drug test that is demonstrate impairment and be forensically defensible (hold up in court of law)?
2. If an employer does a test that does not demonstrate impairment, what will the imposed penalty be?
The response from OSHA to the above questions were: “OSHA is in the process of developing detailed guidance for our field staff and will address this issue there.”
The drug test questions and impairment are part of the motion that was filed by MCLA.
The drug testing industry and employers will have to wait and see what the response from OSHA will be. There are several options that can take place outlined below.
- The final rule will be canceled (not very likely;
- There will be a rewrite of the final rule with a notice of proposed rulemaking to take place; more viable option).
- They will leave the final rule in place as written (highly unlikely).
Right now employers and the drug test industry are in a holding pattern of wait and see.
My personal opinion is that OSHA with the use of the word “impairment” was not prepared for the reaction that they have received and had little or no understanding of drug testing and what the word “impairment” means in the world of forensic drug testing.
Article by:Bob Schoening
Robert Schoening is well renowned for his knowledge and influence in the drug-testing arena. As the Drug and Alcohol Program Manager for the US Coast Guard (December 2001-March 2013) he developed and managed a successful drug testing program for the marine industry nationwide and internationally. During this time he developed and implemented a new compliance audit checklist as well as the writing and publishing a new Marine Employers Guidebook for Drug Testing. He is also the author of the federal regulation commonly known as the two-hour alcohol testing for maritime incidents.
Robert’s drug testing career began in the Navy Medical Department, where he received the Navy Achievement Medal for his work on development of the Navy drug-testing program which was the first major workplace drug-testing program in the country. He retired in 1985 after serving 24 years.
Upon his retirement, Robert established his own drug testing consulting company assisting other companies to establish drug-free workplaces and drug testing programs, concentrating primarily on the marine industry. His knowledge of regulations and policy helped build his company to be one of the premier providers of drug testing services for the marine industry. During this time he was instrumental in establishing many of the current federal policies that are in place.
Robert has served on the Board of Directors of the Substance Abuse Program Administrators Association (SAPAA) as well as chairing the Governmental and Legislative Affairs committee. He was one of the first individuals to be recognized as an expert in the Drug and Alcohol testing industry and to receive designation as a Certified Substance Abuse Program Administrator (1996).
Robert is active participant in community service. He recently served on the Policy Board for the Alcohol Safety Action Program in Fairfax, VA (January 1989-December 2012). Since moving to Whidbey Island in Washington, he has been named to serve on the Substance Abuse Committee and recently been named to serve on the Ferry Advisory Committee both of these committees are located in Island County, WA.
Robert is currently a consultant for Workplace Drug Testing and Drug Abuse Prevention Programs.